+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Analysis on functional heterogeneity of lymphokine activated killer lak cells and tumor infiltrating lymphocytes til at the clonal level

Analysis on functional heterogeneity of lymphokine activated killer lak cells and tumor infiltrating lymphocytes til at the clonal level

Sapporo Medical Journal 60(2): 205-214

We have analyzed interleukin-2 stimulated killer activity derived from peripheral blood lymphocytes (PBL) and tumor infiltrating lymphocytes (TIL) at the clonal level by a limiting dilution technique. The number of obtained clones from LaK and TIL were 34 and 78, respectively. The killer activity of these clones was examined against autologous tumor cells and Daudi cells as targets. About half of the PBL and TIL clones showed significant cytotoxicity against autologous tumor and/or Daudi cells. It was noteworthy that the specific cytotoxicity against autologous tumor cells (CTL-Like activity) was observed in 9 of 14 LAK killer clones and in 30 of 41 TIL killer clones. Surface marker analysis indicated that all the CTL-like clones were either CD3+4+8- or CD3+4-8+, and there was no significant difference in cytotoxicity between them. On the other hand, about half of the LAK and TIL clones had no cytotoxic effect against Daudi and/or autologous tumor cells. On the CTL induction system, these non-killer clones also showed regulatory functions, such as augmentation and suppression. These results suggest that IL-2 activated cells, both from peripheral blood and tumor tissue have not only a direct cytotoxic activity, but also an indirect helper function which was mediated by regulatory T cell.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 007018795

Download citation: RISBibTeXText

Related references

Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid: prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity. Journal of Clinical Endocrinology and Metabolism 69(4): 832-836, 1989

Membrane-associated lymphotoxin expression and functional analysis of lymphokine-activated killer cells derived from tumor-infiltrating lymphocytes. Japanese Journal Of Cancer Research. 84(11): 1165-1173, 1993

Three color immunofluorescence analysis of phenotypic differences between lymphokine activated killer cells and tumor infiltrating lymphocytes. Cytometry (Suppl. 1): 8, 1987

Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes. Cellular Immunology 100(1): 149-157, 1986

Lymphokine-activated killer-cells and tumor-infiltrating lymphocytes in metastatic melanoma. Journal of Cancer Research & Clinical Oncology 120(Suppl. ): R129, 1994

Heterogeneity of lymphokine-activated killer (LAK) populations at the clonal level: both NK and CD3+, CD4-, CD8- clones efficiently mediate tumor cell killing. Clinical Immunology and Immunopathology 49(1): 91, 1988

Lymphokine-activated killer cells/tumor-infiltrating lymphocytes therapy: efficacy, toxicity, controversies. Journal of Clinical Apheresis 5(2): 80-82, 1990

Mechanims of adoptive immunotherapy: Improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Research 53(10): 2358-2367, 1993

Influence of IFN-gamma on human renal cell carcinomas and their altered recognition by tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Immunobiology 191(2-3): 214, 1994

Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Cancer Research 48(5): 1180-1183, 1988

Heterogeneity of lymphokine activated killer lak populations at the clonal level both nk and cd3 positive cd4 negative cd8 negative clones efficiently mediate tumor cell killing. Clinical Immunology & Immunopathology 49(1): 91-100, 1988

Antitumor and proliferative responses of il 2 expanded tumor infiltrating lymphocytes til vs lymphokine activated killer lak cells derived from patients with advanced renal cell cancer rcc. Federation Proceedings: 1508, 1987

Tumor infiltrating lymphocytes isolated from a ki 1 positive large cell lymphoma of the skin phenotypic characterization and analysis of lymphokine secretion at the clonal level. Archives of Dermatological Research 281(8): 555-556, 1990

Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes. Clinical Immunology and Immunopathology 59(3): 407-416, 1991

Monoclonal antibodies anti-CD3, anti-TCR alpha beta and anti-CD2 act synergistically with tumor cells to stimulate lymphokine-activated killer cells and tumor-infiltrating lymphocytes to secrete interferon gamma. Cancer Immunology ImmunoTherapy 35(5): 335-341, 1992